1. Evidence of deficiency of, antagonism to, or abnormal dependency upon pyridoxine has been sought in four patients with primary hyperoxaluria. The urinary excretion of kynurenine, 3-hydroxykyurenineY 3-hydroxyanthranilic acid, kynurenic acid and xanthurenic acid, before and after a loading dose of L-tryptophan was used to assess pyridoxine nutrition.
oxalate stones in non-hyperoxaluric patients on the basis of their elevated xanthurenic acid excretion after a tryptophan load. Ludwig (1963) also reported a patient with a 'relative deficiency' of pyridoxine as judged by this criterion and a mild degree of hyperoxaluria, which was corrected by pyridoxine treatment.
Pyridoxine deficiency, or antagonism, produces characteristic changes in the excretion of kynurenine (Kyn), 3-hydroxykynurenine (OHKyn), 3-hydroxyanthranilic acid (OHAntA), kynurenic acid (KynA) and xanthurenic acid (XanA) particularly after an oral dose of Ltryptophan (O'Brien & Jensen, 1963; Price, Brown & Yess, 1965; Heeley, 1965; Gibbs & Watts, 1969a) . The relationships of these compounds to one another and to the biosynthesis of nicotinic acid are summarized in Fig. 1 . The present work was undertaken to determine if patients with primary hyperoxaluria show evidence of pyridoxine deficiency or abnormal dependency, and to compare these results with the effect of pyridoxine on the urinary oxalate excretion.
I T R Y P T O P H

P A T I E N T S A N D M E T H O D S
The methods described by Gibbs &Watts (1969a) were used for the tryptophan load tests and for the determination of kynurenine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, kynurenic acid and xanthurenic acid in urine. Urinary oxalate was measured by isotope dilution analysis (Gibbs & Watts, 1969b) . The plasma pyridoxal was measured by the method of Anderson, Peart & Fulford-Jones (1 969).
The patients were all studied when they were hospitalized but ambulant on the Metabolic Ward, except where indicated. They were given a self-selected repetitive diet. Pyridoxine supplements were in the form of the hydrochloride. Patient 1 is a female now aged 17 years who has been studied previously ('subject 3', Crawhall & Watts, 1962; 'patient 3', Gibbs & Watts, 1967; Dean, Watts & Westwick, 1968) . She has numerous bilateral renal calculi but was asymptomatic when the present studies were made ; blood urea 39 mg/100 ml, inulin clearance 58 ml min-' 1.73 m-', plasma pyridoxine, 3.2 ng/ml before being given pyridoxine (this value is within the range observed for control subjects by Dr B. Anderson). This patient's diet was calculated to supply: protein 33 g/24 hr, fat 37 g/24 hr, carbohydrate 302 g/24 hr and 1715 kca1/24 hr.
Patient 2 is an asymptomatic 11-year-old boy, previously studied by Gibbs & Watts (1968) . He had no radiologically demonstrable urinary calculi; blood urea 36 mg/100 ml, inulin clearance 102 ml min-' 1.73 m-', PAH clearance 572 ml min-' 1.73 m-2. His diet was calculated to supply: protein 56 g/24 hr, fat 105 g/24 hr, carbohydrate 322 g/24 hr and 2414 kcal/ 24 hr.
Patient 3 is a previously unreported asymptomatic 6-year-old girl with a small number of calculi in both kidneys; blood urea 24 mg/100 ml, creatinine clearance 107 ml min-' 1.73 m-'. Her diet was calculated to supply: protein 32 g/24 hr, fat 53 g/24 hr, carbohydrate 287 g/24 hr and 1750 kca1/24 hr. The urinary oxalate excretion of this patient is shown in Fig. 4 .
Patient 4 is a previously unreported 36-year-old woman who has bilateral nephrocalcinosis and bilateral calculi, but who had no symptoms of urinary stones until she was 30 years old. Her urinary oxalate excretion is in the range 165-235 mg anhydrous oxalic acid 24 hr-' 1-73 m-', blood urea 43 mg/100 ml, inulin clearance 84 ml min-' 1.73 m-', PAH clearance 356 ml min-' 1.73 m-'. Her diet was calculated to supply: protein 76 g/24 hr, fat 84 g/24 hr, carbohydrate 257 g/24 h r and 2170 kca1/24 hr.
R E S U L T S
The urinary excretion of the tryptophan metabolites, expressed as a series of ratios, precursor excretion/product excretion, and the effect of pyridoxine is shown in Table 1 , together with the previously published range of normal values obtained in this laboratory (Gibbs & Watts, 1969a) . The experimental data, in the form of 24-hr excretion values, are given in a Table (Clinical Science  Table 38 /3) deposited with the Librarian, The Royal Society of Medicine, from whom copies may be obtained.
The oral administration of pyridoxine to patients 2 and 3 reduced their urinary oxalate excretion to levels which were intermediate between the normal range defined by Gibbs & Watts (1969b) and the lower limit of the range of two standard deviations about the mean value for the corresponding control period when pyridoxine was not given (Figs. 2, 3 and 4) . This effect has been maintained for about 6 months (Figs. 3 and 4) , but increasing the dose above 150 mg/24 hr, given as equally divided and equally spaced doses, did not increase the magnitude of the effect (Fig. 4) .
D I S C U S S I O N
The steps on the L-tryptophan-nicotinic acid metabolic pathway which depend on pyridoxine, in the form of pyridoxal phosphate, are shown in Fig. 1 . The conversion of 3-hydroxykynuren- ine to 3-hydroxyanthranilic acid (the kynureninase reaction) is more sensitive to pyridoxine deficiency or antagonism than the transamination reactions which convert kynurenine and 3-hydroxykynurenine to the immediate non-cyclized precursors of kynurenic acid and xanthurenic acid respectively. The excretion of 3-hydroxykynurenine, xanthurenic acid and kynurenic acid is increased in moderately severe pyridoxine deficiency, but the excretion of the latter two compounds is an unreliable index of severe pyridoxine deficiency because of the pyridoxal phosphate dependency of the transaminases. The present results are expressed as a series of ratios, precursor excretion/product excretion (Table l) , as well as in the form of 24-hr excretion values in order to improve the discrimination between normal and pyridoxine deficient subjects (OBrien & Jensen, 1963; Heeley, 1965; Gibbs & Watts, 1969a) . The excretion ratio OHKyn/ OHAntA is the most sensitive indirect index of pyridoxine deficiency because of the high degree of pyridoxal phosphate dependency of the kynureninase reaction (O'Brien & Jensen, 1963; Coursin, 1964) . Changes in the excretion ratios Kyn/KynA and OHKyn/OHAntA would depend on the relative degree of impairment of the kynureninase and transamination reactions. The ratio Kyn/KynA would be expected to be low in moderately severe pyridoxine deficiency with impaired kynureninase activity but relatively intact transaminase activity because of increased kynurenic acid production from accumulated kynurenine. This ratio would also be expected to increase as the degree of pyridoxine deficiency increased and the transaminase activity became impaired. The excretion ratio Kyn/OHKyn depends on the activity of the NADPHl dependent enzyme system, kynurenine 3-hydroxylase (EC 1.99.1.5) and is not therefore affected by pure pyridoxine deficiency or antagonism (Gibbs & Watts, 1969a) . Restriction of the kynurenine 3-hydroxylase step alone would be expected to raise the Kyn/OHKyn excretion ratio. This would, however, also be influenced by the extent to which the capacity of the alternative metabolic pathways leading away from kynurenine, including transamination and cyclization to kynurenic acid, could increase to prevent kynurenine accumulation. In the present investigation, patients 1, 2 and 3 show high values for the excretion ratio Kyn/OHKyn upon tryptophan loading and generally also for the Kyn/KynA excretion ratio. The values for Kyn/OHAntA, which depends on both the kynurenine 3-hydroxylase and the kynreninase reactions, is also sometimes increased, whereas the values for the excretion ratio OHKyn/OHAntA are normal. These alterations differ from those which characterize pyridoxine depletion or antagonism, being of the type which would be predicted for reduced kynurenine 3-hydroxylase activity (vide supra). Also, the intramuscular injection of amounts of pyridoxine which have been shown to reverse the biochemical changes of pyridoxal phosphate antagonism (Gibbs 8c Watts, 1969a) did not affect the abnormal ratios Kyn/OHKyn on the day of the tryptophan load, but Kyn/OHAntA and Kyn/KynA were corrected. It appears probable that in the absence of any change in the OHKyn/OHAntA excretion ratio, pyridoxine was acting specifically on the kynurenine transaminase reaction in this instance, possibly as an enzyme inducer (Greengard & Gordon, 1963) .
It is difficult to correlate the evidence suggesting reduced conversion of kynurenine to 3-hydroxykynurenine in patients 1 , 2 and 3 of the present study with most of the other biochemical changes which have been reported in primary hyperoxaluria, and the patients do not show any clinical evidence of nicotinic acid deficiency. It is of interest, however, that Williams 8c Smith (1967 Smith ( ,1968 reported cases of primary hyperoxaluria who lack the NADHz or NADPH, dependent D-glyceric dehydrogenase.
Previous studies of the effect of pyridoxine on the urinary oxalate excretion in primary hyperoxaluria have yielded inconclusive or contradictory results. McLaurin et al. (1961) reported that it had no effect, whereas Smith & Williams (1967) present data on four patients whose average urinary oxalate excretion was reduced by about 25% during pyridoxine treatment. However, the ranges of the values for the pretreatment and treatment periods overlapped extensively in three of their patients and no statistical analysis of the results is available. Patient 1 in the present study had been given pyridoxine without effect in a previous investigation (Gibbs 8c Watts, 1967) . This patient has recently been re-investigated and the negative result confirmed (Gibbs & Watts, unpublished) . The present observations on patients 2 and 3 establish that pyridoxine produces a sustained reduction in the urinary oxalate excretion in some cases. This cannot, however, be correlated with the correction of a state of pyridoxine deficiency as judged by the results of studying the excretion of tryptophan metabolities.
Glyoxylate is the main immediate metabolic precursor of the urinary oxalate, and increasing the metabolism of this compound by alternate metabolic pathways would be expected to reduce the urinary oxalate excretion. Pyridoxine can induce synthesis of the corresponding apoenzyme (Greengard & Gordon, 1963) , and induction of a glyoxylate transaminase could explain an effect of pyridoxine on urinary oxalate excretion without implying that pyridoxine metabolism is altered in primary hyperoxaluria or that the fundamental metabolic lesion or lesions (Dean, Griffin t Watts, 1966; Dean, Watts 8c Westwick, 1967; Koch et al., 1967) hasbeencorrected.
Hollowell et al. (1968) reported a similar observation in homocystinuria. The urinary excretion of homocystine was greatly reduced by pyridoxine, although it was proved that the total lack of cystathionine synthetase [L-serine hydrolase (deaminating) (EC 4.2.1.13)] was uninfluenced, and the authors concluded that pyridoxine increased the metabolism of methionine by alternative metabolic pathways. 
